Altimmune, Inc. ALT
Altimmune, Inc. (Nasdaq: ALT) is a GI/hepatology drug developer. Its lead program, pemvidutide, is in Phase 3 for MASH. Its next catalyst on record is pemvidutide: 52-week PERFORMA Phase 3 readout (2029).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: pemvidutide — 52-week PERFORMA Phase 3 readout (2029). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| pemvidutide | MASH | protein/peptide | Phase 3 |
Recent results and decisions
- Aug 12, 2026started Global PERFORMA Phase 3 MASH trial initiated; 52-week data readout anticipated 2029.
In August 2026, the Company announced the initiation of the global PERFORMA Phase 3 MASH trial, with 52-week data readout anticipated in 2029
Filing - Aug 12, 2026completed enrollment Enrollment completed in the RESTORE Phase 2 ALD trial (~120 patients) in July 2026.
In July 2026, the Company completed patient enrollment in the RESTORE Phase 2 trial of pemvidutide in ALD
Filing - Jul 28, 2026met RECLAIM met primary endpoint: heavy drinking days/week change -4.20 vs -2.75 placebo (diff -1.45, p=0.0014); 2-level WHO-RDL reduction 64.4% vs 34.8% (p=0.0049).
The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days (HDD) versus placebo
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.